Search results :

LMWH

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: B01AB05

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9
Dyspnoea 3.3% 5.2% x x x x x x x x x
Nausea 1% - 3% 0% - 2% x x x x x x x x x
Confusional state 2.2% 1.1% x x x x x x x x x
Diarrhoea 2.2% 1.7% x x x x x x x x x
Haemorrhage 0% - 13% 0% - 3% x x x x x x x x x
Anaemia 0% - 16% 1% - 7% x x x x x x x x x
Oedema 1% - 2% 0% - 2% x x x x x x x x x
Ecchymosis 0% - 3% x x x x x x x x x
Thrombocytopenia postmarketing, 1.5% - 2.8% 2.8% x x x x x x x x x
Cardiac failure 0.951% x x x x x x x x x
Haemorrhage intracranial 0.825% x x x x x x x x x
Pneumonia 0.824% x x x x x x x x x
Atrial fibrillation 0.697% x x x x x x x x x
Pulmonary oedema 0.697% x x x x x x x x x
Body temperature increased 0% - 8% 0% - 3% x x x x x x x x x
Haematuria 0% - 2% x x x x x x x x x
Oedema peripheral 0% - 6% 0% - 3% x x x x x x x x x
Injection site haemorrhage 0% - 5% x x x x x x x x x
Alopecia postmarketing x x x x x x
Eosinophilia postmarketing x x x x x x
Headache postmarketing x x x x x x
Haematoma postmarketing x x x x x x x x x
Hyperkalaemia postmarketing x x x x x x x x x
Hyperlipidaemia postmarketing x x x x x x x x x
Hypersensitivity postmarketing x x x x x x x x x
Hypertriglyceridaemia postmarketing x x x x x x x x x
Inflammation postmarketing x x x x x x x x x
Nodule postmarketing x x x x x x x x x
Osteoporosis postmarketing x x x x x
Pruritus postmarketing x x x x x x x x x
Purpura postmarketing x x x x x x x x x
Shock postmarketing x x x x x
Thrombosis postmarketing x x x x x x x x x
Urticaria postmarketing x x x x x x x x x
Vasculitis postmarketing x x x x x x x x x
Skin necrosis postmarketing x x x x x x x x x
Vesiculobullous rash postmarketing x x x x x x x x x
Diabetic postmarketing x x x x x x x x x
Anaphylactoid reaction postmarketing x x x x x x x x x
Paralysis postmarketing x x x x x x x x x
Cutaneous hypersensitivity postmarketing x x x x x x x x x
Thrombocytosis postmarketing x x x x x x x x x
Local reaction postmarketing x x x x x x x x x
Spinal haematoma postmarketing x x x x x x x x x
Haemorrhagic anaemia postmarketing x x x x x x
Cholestatic liver injury postmarketing x x x x x x
Liver disorder x x x x x x x x x
Pain x x x x x x x x x
Erythema x x x x x x x x x
Injection site pain 0% - 2% x x x x x x x x x
Aspartate aminotransferase increased x x x x x x x x x
Alanine aminotransferase increased x x x x x x x x x
Sickness x x x x x x x x x
Epidural haemorrhage x x x x x x x x x
Electrocardiogram ST segment elevation x x x x x x x x x
Non-Q wave MI x x x x x x x x x
Major bleed x x x x x x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

ENOXAPARIN

Side effects:50
Source:FDA Structured Product Label

ENOXAPARIN

Side effects:50
Source:FDA Structured Product Label

ENOXAPARIN

Side effects:50
Source:FDA Structured Product Label

enoxaparin

Side effects:56
Source:FDA Structured Product Label

enoxaparin

Side effects:56
Source:FDA Structured Product Label

ENOXAPARIN

Side effects:57
Source:FDA Structured Product Label

enoxaparin

Side effects:57
Source:FDA Structured Product Label

enoxaparin

Side effects:57
Source:FDA Structured Product Label

enoxaparin

Side effects:57
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label